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Low WT1 transcript levels at diagnosis 
predicted poor outcomes of acute myeloid 
leukemia patients with t(8;21) who received 
chemotherapy or allogeneic hematopoietic 
stem cell transplantation
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Abstract 
Background: Acute myeloid leukemia (AML) with t(8;21) is a heterogeneous disease. Identifying AML patients with 
t(8;21) who have a poor prognosis despite achieving remission is important for determining the best subsequent 
therapy. This study aimed to evaluate the impact of Wilm tumor gene‑1 (WT1) transcript levels and cellular homolog 
of the viral oncogene v‑KIT receptor tyrosine kinase (C‑KIT) mutations at diagnosis, and RUNX1‑RUNX1T1 transcript 
levels after the second consolidation chemotherapy cycle on outcomes.
Methods: Eighty‑eight AML patients with t(8;21) who received chemotherapy only or allogeneic hematopoietic 
stem cell transplantation (allo‑HSCT) were included. Patients who achieved remission, received two or more cycles 
of consolidation chemotherapy, and had a positive measureable residual disease (MRD) test result (defined as <3‑log 
reduction in RUNX1‑RUNX1T1 transcript levels compared to baseline) after 2–8 cycles of consolidation chemotherapy 
were recommended to receive allo‑HSCT. Patients who had a negative MRD test result were recommended to receive 
further chemotherapy up to only 8 cycles. WT1 transcript levels and C‑KIT mutations at diagnosis, and RUNX1‑RUNX1T1 
transcript levels after the second consolidation chemotherapy cycle were tested.
Results: Patients who had a C‑KIT mutation had significantly lower WT1 transcript levels than patients who did not 
have a C‑KIT mutation (6.7% ± 10.6% vs. 19.5% ± 19.9%, P < 0.001). Low WT1 transcript levels (≤5.0%) but not C‑KIT 
mutation at diagnosis, a positive MRD test result after the second cycle of consolidation chemotherapy, and receiv‑
ing only chemotherapy were independently associated with high cumulative incidence of relapse in all patients 
(hazard ratio [HR] = 3.53, 2.30, and 11.49; 95% confidence interval [CI] 1.64–7.62, 1.82–7.56, and 4.43–29.82; P = 0.002, 
0.034, and <0.001, respectively); these conditions were also independently associated with low leukemia‑free survival 
(HR = 3.71, 2.33, and 5.85; 95% CI 1.82–7.56, 1.17–4.64, and 2.75–12.44; P < 0.001, 0.016, and <0.001, respectively) and 
overall survival (HR = 3.50, 2.32, and 4.34; 95% CI 1.56–7.82, 1.09–4.97, and 1.98–9.53; P = 0.002, 0.030, and <0.001, 
respectively) in all patients.
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Background
Patients who have acute myeloid leukemia (AML) with 
t(8;21) have a better prognosis than those with other 
cytogenetic subtypes [1, 2]. Nevertheless, 30%–40% of 
patients with t(8;21) relapse, and many die of advanced 
leukemia [3–5]. Consequently, identifying AML patients 
with t(8;21) who have a poor prognosis despite achieving 
remission is important for determining the best subse-
quent therapy.
Several variables are associated with outcomes in AML 
patients with t(8;21) [3, 5–14]. Some variables can be 
ascertained at diagnosis, some after therapy, and oth-
ers either at diagnosis or after therapy. Many of these 
variables are confounded. For example, the association 
between cellular homolog of the viral oncogene v-KIT 
receptor tyrosine kinase (C-KIT) mutation at diagnosis 
and poorer outcomes after chemotherapy is masked by 
the predictive value of Runt-related transcription factor 
1-RUNX1 translocation partner 1 (RUNX1-RUNX1T1) 
transcript levels after achieving remission [12, 13]. This 
is not surprising since response to therapy is usually a 
better predictor of outcomes than a measurement at 
diagnosis.
Wilm tumor gene-1 (WT1) is a transcription factor 
overexpressed in diverse neoplasms, including AML. We 
and others reported that more than 70% of AML patients 
with overexpressed WT1 at diagnosis [15–18]. Studies 
in mice indicated that, in some settings, WT1 overex-
pression was required for the development of leukemia 
[19]. Whether WT1 transcript levels at diagnosis pre-
dict outcomes of AML patients is controversial [20–26]. 
No study has examined AML patients with t(8;21) who 
achieved remission.
In our study, we examined 88 AML patients with 
t(8;21) who enrolled in the multicenter AML05 trial 
(registered at http://www.chictr.org as #ChiCTR-
OCH-12002406); after achieving remission, these 
patients received chemotherapy only or allogeneic 
hematopoietic stem cell transplantation (allo-HSCT) 
[13]. We evaluated the association between WT1 tran-
script levels at diagnosis and therapy outcomes, after 
adjusting for other potential prognostic variables, 
including C-KIT mutations at diagnosis and RUNX1-




Between January 2007 and December 2012, 124 consecu-
tive AML patients with t(8;21) (median age 37 years; age 
range 14–60  years) from three centers (Peking Univer-
sity People’s Hospital, Beijing No. 6 Hospital, and Beijing 
Rehabilitation Hospital) were enrolled in the AML05 
trial. After one or two cycles of induction chemotherapy, 
108 patients achieved complete remission; of these, 101 
patients had high-quality RNA samples extracted from 
bone marrow mononuclear cells at diagnosis.
As we previously reported [13], induction chemother-
apy was composed of 1–2 cycles of induction with an 
anthracycline (either daunorubicin 45  mg/m2 or idaru-
bicin 8–10 mg/m2 for 3 days) in combination with cytara-
bine 100 mg/m2 for 7 days. The first and second cycles of 
consolidation chemotherapy included intermediate-dose 
cytarabine (IDAC 1–2 g/m2 every 12 h for 3 days) with 
or without an anthracycline (daunorubicin 45 mg/m2 or 
mitoxantrone 8  mg/m2 for 3  days). Post-consolidation 
chemotherapy was performed as reported previously 
[13], which included IDAC for 2 cycles, then followed by 
daunorubicin/idarubicin in combination with cytarabine, 
homoharringtonine with cytarabine, mitoxantrone with 
cytarabine, or aclamycin with cytarabine. Among the 
101 patients, 1 received no further therapy, 42 received 
1–6 cycles of post-consolidation chemotherapy, and 13 
received 1–4 cycles of post-consolidation chemotherapy 
followed by autologous-hematopoietic stem cell trans-
plantation (auto-HSCT); the remaining 45 received no 
post-consolidation chemotherapy (n = 7) or 1–6 courses 
of post-consolidation chemotherapy (n  =  38), followed 
by allo-HSCT from a human leukocyte antigen (HLA)-
identical sibling (n = 22), a HLA haplotype-matched rela-
tive (n = 19), or a HLA-matched unrelated donor (n = 4). 
Therapy recommendation was based on the results of 
measureable residual disease (MRD) testing [27] after 
2–8 cycles of consolidation chemotherapy. The real treat-
ment selection was based on both physician’s recommen-
dation and patient’s preference.
RNA extraction, real-time quantitative polymerase 
chain reaction (RQ-PCR) testing, and C-KIT mutation 
testing were performed at Peking University Institute of 
Hematology. The cutoff date for follow-up was October 
31, 2014. We did not consider WT1 transcript levels at 
Conclusions: Testing for WT1 transcript levels at diagnosis in patients with AML and t(8;21) may predict outcomes in 
those who achieve remission. A randomized study is warranted to determine whether allo‑HSCT can improve prog‑
nosis in these patients.
Keywords: Acute myeloid leukemia, RUNX1‑RUNX1T1 transcript level, WT1 transcript level, C‑KIT mutation, Allogeneic 
hematopoietic stem cell transplantation
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diagnosis when deciding what post-consolidation therapy 
was received by patients who achieved remission and 
received consolidation chemotherapy.
Ethics, consent, and permissions
Our study was approved by the Ethics Committee of 
Peking University People’s Hospital. In accordance with 
the Declaration of Helsinki, all patients offered signed 
informed consent to participate in the study.
RNA extraction and complementary DNA (cDNA) synthesis
Trizol Reagent (Invitrogen, Carlsbad, CA, USA) was used 
to extract total RNA. A High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA, 
USA) was used to synthesize cDNA.
Detection of RUNX1‑RUNX1T1 and WT1 transcripts
As described previously, TaqMan-based RQ-PCR tech-
nology was used to detect RUNX1-RUNX1T1 and WT1 
transcript levels [18, 28–30]. Primer and probe sequences 
for Abelson (ABL) and RUNX1-RUNX1T1 from the 
report of the Europe against cancer program [31, 32] 
were used. Primer and probe sequences used for WT1 
detection were performed as those published previously 
[30, 33]. Transcript levels were calculated as percent of 
RUNX1-RUNX1T1 or WT1 transcript copies/ABL cop-
ies. We previously identified an upper limit of 0.5% of 
WT1 transcript level detection in normal bone marrow 
samples [18].
In a prior study, the median baseline level of RUNX1-
RUNX1T1 transcripts was 388% (range 138%–848%) [34]. 
We defined a positive MRD test result as a less than 3-log 
reduction in RUNX1-RUNX1T1 transcript level com-
pared to baseline (>0.4%) after the second cycle of con-
solidation chemotherapy. Although a positive or negative 
MRD test result after the second cycle of consolidation 
chemotherapy was used in the univariate and multivari-
ate analyses, therapy recommendations were based on 
results of MRD testing at each time point.
Detection of C‑KIT mutations in exons 17 and 8
cDNA was used for PCR to detect C-KIT mutations in 
exons 17 and 8 [10]. The PCR products were analyzed 
by bidirectional sequencing on an ABI 3730 sequencer 
(Applied Biosystems). Sensitivity of mutation detection 
was 10%–20%.
Statistical analyses and definitions
Fisher’s exact test was used to compare the differences 
in variable frequencies between cohorts. Martingale 
residual plot and receiver operating characteristic (ROC) 
curves based on overall mortality were used to determine 
the potentially optimal WT1 cutoff levels. Survival func-
tions were estimated using the Kaplan–Meier method 
and compared by the log-rank test within the same treat-
ment group. The starting point for comparing outcomes 
between the cohorts was the point when complete remis-
sion was declared. Left-truncated analyses were used 
to eliminate the potential bias caused by the relapse or 
death which made the patient unable to receive an allo-
HSCT. At each study time point in this model, the risk set 
in the non-transplant cohort consisted of all patients who 
were still in the study, whereas the risk set in the trans-
plant cohort included only patients whose waiting time 
to undergo allo-HSCT was shorter than the current study 
period and who were still in the study.
Univariate probabilities of overall survival (OS) and 
leukemia-free survival (LFS) were calculated using a left-
truncated version of the Kaplan–Meier estimator with 
95% confidence intervals (CIs). To accommodate com-
peting risks, cumulative incidence of relapse (CIR) and 
treatment-related mortality (death in complete remis-
sion) were calculated using a left-truncated version of the 
cumulative incidence function (CIF). To adjust for the 
differences in baseline characteristics, left-truncated ver-
sions of the Cox proportional hazards regression models 
were used to evaluate the relative risk of patients who 
received chemotherapy only versus those who received 
allo-HSCT. The proportionality assumption was tested 
by adding a time-dependent covariate. A backward step-
wise model selection approach was used to identify all 
significant risk factors. Furthermore, we analyzed the 
association of variables with clinical outcomes in the 
chemotherapy-only and allo-HSCT cohorts. Results of 
the multivariate analysis were confirmed by fitting a Cox 
model with a time-dependent treatment assignment 
in which all patients were considered non-transplant 
patients and were switched to the transplant cohort 
when the current study time point passed each individ-
ual’s transplant time. LFS was measured from the date 
that complete remission was detected. Events for LFS 
included relapse or death after achieving complete remis-
sion. Patients or their relatives were queried at the date 
of the last follow-up or censored on the date the patients 
were last known to be alive. P values less than or equal to 
0.05 were considered statistically significant. SAS version 
9.3 (SAS Institute Inc., Cary, NC, USA) and SPSS ver-
sion 13.0 (IBM Corporation, Armonk, NY, USA) software 
packages and GraphPad Prism 5 (GraphPad Software, 
Inc., La Jolla, CA, USA) were used for data analyses. 
Standard definitions of complete remission and relapse 
were used as reported previously [35]. Relapses included 
those occurred at the bone marrow and/or extra-medul-
lary sites.
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Results
Patients and outcomes
Among the 101 patients studied, median follow-up 
time for those who survived was 38  months (range 
4–93  months). Twenty-six chemotherapy-only patients, 
1 auto-HSCT patient, and 6 allo-HSCT patients expe-
rienced a relapse. Twenty-two chemotherapy-only 
patients, 14 auto-HSCT patients, and 35 allo-HSCT 
patients were alive at last follow-up. Three-year CIR, LFS, 
and OS rates are shown in Table 1.
Owing to the small number of auto-HSCT patients 
(n  =  13), the 88 patients who received allo-HSCT 
(n = 45) or chemotherapy only (n = 43, including 1 who 
received no further chemotherapy after two cycles of 
consolidation chemotherapy) were the basis of our sub-
sequent analysis. Patient characteristics at diagnosis are 
shown in Table  2. In any variable tested, no significant 
differences were observed between the chemotherapy-
only cohort and the allo-HSCT cohort.
Determining the best WT1 transcript breakpoint
The Martingale residuals plot indicated that the poten-
tial breakpoint for WT1 level was 5.0%–10.0%. We 
identified 5.0% (≤5.0% vs. >5.0%) as the most appropriate 
WT1 breakpoint using the maximized partial likelihood 
method. In this study, 5.0% was the largest likelihood 
among 5.0%, 8.0%, and 10.0%. The same WT1 level break-
point was identified through ROC curve analyses (data 
not shown). Based on these data, 40 patients with WT1 
transcript levels ≤5.0% at diagnosis were characterized as 
having low WT1 transcript levels, and 48 patients were 
characterized as having high WT1 transcript levels.
Relationship between WT1 transcript level and C‑KIT 
mutation at diagnosis
Among 88 patients, 82 (93.2%) had WT1 overexpression 
(transcript level >0.5%) at diagnosis, including 48 (54.5%) 
had WT1 overexpression  >1-log above the upper limit 
of normal bone marrow cells (transcript level  >5.0%). 
Thirty patients had C-KIT mutations detected at diag-
nosis. Patients who had a C-KIT mutation had signifi-
cantly lower WT1 transcript levels than those who did 
not have a C-KIT mutation (mean ± standard deviation: 
6.7% ± 10.6% vs. 19.5% ± 19.9%, P < 0.001; Fig. 1).
Forty patients had high WT1 transcript levels and no C-
KIT mutation, 22 patients had low WT1 transcript levels 
and a C-KIT mutation, 18 patients had low WT1 transcript 
levels and no C-KIT mutation, and 8 patients had high 
WT1 transcript levels and a C-KIT mutation. Having low 
WT1 transcript levels at diagnosis was significantly associ-
ated with C-KIT mutation (22 of 40 vs. 8 of 48; P < 0.001).
Associations of WT1 transcript level and C‑KIT mutation 
at diagnosis with outcomes
Of the 43 patients who received chemotherapy only, 17 
who had low WT1 transcript levels at diagnosis had sig-
nificantly higher 3-year CIR and lower LFS and OS rates 
than the 26 patients who had high WT1 transcript lev-
els at diagnosis (CIR 100% vs. 44% [95% CI 32%–56%], 
P < 0.001; LFS 0% vs. 51% [95% CI 26%–71%], P < 0.001; 
Table 1 Unadjusted outcomes at 3 years of acute myeloid 
leukemia (AML) patients with  t(8;21) who achieved com-
plete remission after 1–2 induction chemotherapy cycles
CIR cumulative incidence of relapse, LFS leukemia-free survival, OS overall 
survival, allo-HSCT allogeneic hematopoietic stem cell transplantation, auto-
HSCT autologous-hematopoietic stem cell transplantation
Group CIR rate LFS rate OS rate
Chemotherapy 
only
71% (63%–80%) 26% (15%–43%) 41% (25%–58%)
Auto‑HSCT 8% (0%–71%) 85% (51%–96%) 92% (57%–99%)
Allo‑HSCT 16% (10%–22%) 72% (56%–83%) 77% (61%–87%)
All cohorts 37% (25%–50%) 56% (45%–65%) 65% (54%–74%)
Table 2 Variables at diagnosis of AML patients with t(8;21) who achieved complete remission and received chemother-
apy only and allo-HSCT
RUNX1-RUNX1T1 Runt-related transcription factor 1-RUNX1 translocation partner 1, C-KIT cellular homolog of the viral oncogene v-KIT receptor tyrosine kinase
a These values are presented as number of patients followed by percentage in parentheses; other values are presented as median followed by a range in parentheses
Variable All Chemotherapy only Allo‑HSCT P value
Total 88 43 45 –
Age (years) 36 (14–60) 42 (14–60) 36 (14–54) 0.36
Malesa 47 (53%) 19 (44%) 28 (62%) 0.13
WBC (×109/L) 8.3 (1.3–112) 8.1 (1.3–112) 8.6 (1.2–83) 0.41
Blast cells percentage in the bone marrow (%) 46% (18%–87%) 46% (23%–87%) 48% (18%–83%) 0.82
Platelet count (×109/L) 29 (4–187) 30 (5–187) 28 (4–106) 0.38
Other cytogenetic abnormality than t(8;21)a 54 (64%) 24 (59%) 30 (70%) 0.36
RUNX1‑RUNX1T1 transcript level 466% (97%–2545%) 532% (186%–2545%) 422% (97%–933%) 0.31
C‑KIT mutationa 30 (34%) 15 (35%) 15 (33%) 1.00
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OS 15% [95% CI 3%–36%] vs. 66% [95% CI 41%–82%], 
P = 0.001; Fig. 2). Similarly, the 15 patients who had a C-
KIT mutation at diagnosis had significantly higher 3-year 
CIR and lower LFS and OS rates than patients without a 
C-KIT mutation (CIR 100% vs. 52% [95% CI 30%–70%], 
P = 0.001; LFS 0% vs. 43% [95% CI 22%–63%], P = 0.002; 
OS 19% [95% CI 3%–44%] vs. 57% [95% CI 34%–74%], 
P = 0.018). The 16 patients who had a positive MRD test 
after the second cycle of consolidation chemotherapy had 
significantly higher 3-year CIR and lower LFS and OS 
rates than the 27 patients who had a negative MRD test 
(CIR 89% [95% CI 79%–95%] vs. 59% [95% CI 39%–75%], 
P  <  0.001; LFS 11% [95% CI 1%–35%] vs. 41% [95% CI 
19%–61%], P < 0.001; OS 25% [95% CI 7%–49%] vs. 58% 
[95% CI 34%–76%], P = 0.001).
Next, we grouped patients undergoing chemotherapy 
only according to WT1 transcript level and C-KIT muta-
tion at diagnosis. The 6 patients who had low WT1 tran-
script levels and no C-KIT mutation had similar 3-year 
CIR, LFS, and OS rates as the 15 patients who had a C-
KIT mutation (11 with low and 4 with high WT1 tran-
script levels at diagnosis; CIR 100% vs. 100%, P = 0.491; 
LFS 0% vs. 0%, P = 0.491; OS 16% [95% CI 1%–32%] vs. 
19% (95% CI 7%–30%), P = 0.640; Fig. 2); these patients 
were merged in further analyses. The 21 patients who had 
Fig. 1 Patients with a cellular homolog of the viral oncogene v‑KIT 
receptor tyrosine kinase (C‑KIT) mutation had significantly lower Wilm 
tumor gene‑1 (WT1) transcript levels at diagnosis than patients who 
did not have a C‑KIT mutation. Line represents median WT1 transcript 
levels
Fig. 2 Both WT1 transcript level and C‑KIT mutation at diagnosis were associated with outcomes in patients who received chemotherapy only. 
Patients were grouped by WT1 transcript level and/or C‑KIT mutation at diagnosis. a, d, g cumulative incidence of relapse (CIR) rate (%); b, e, h 
leukemia‑free survival (LFS) rate (%); c, f, i overall survival (OS) rate (%). Each row has the same labels that are shown on the right of the row
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low WT1 transcript levels or C-KIT mutation at diagno-
sis had a significantly higher 3-year CIR and worse LFS 
and OS than the 22 patients with high WT1 transcript 
levels and no C-KIT mutation (CIR 100% vs. 36% [95% 
CI 9%–65%], P  <  0.001; LFS 0% vs. 57% [95% CI 30%–
78%], P < 0.001; OS 16% [95% CI 3%–37%] vs. 71% [95% 
CI 43%–87%], P = 0.001; Fig. 2). Based on these data, we 
classified patients who had low WT1 transcript levels or a 
C-KIT mutation at diagnosis as being high-risk and those 
with high WT1 transcript levels and no C-KIT mutation 
at diagnosis as being low-risk. Using WT1 transcript lev-
els at diagnosis allowed us to reclassify six patients as 
high-risk compared to using C-KIT mutation state data 
only to calculate risk.
Allo‑HSCT outcomes
Forty-five patients received allo-HSCT. Patients with low 
WT1 transcript levels at diagnosis (n  =  23) had 3-year 
CIR, LFS, and OS rates similar to patients with high 
WT1 transcript levels at diagnosis (n = 22; CIR 13% [95% 
CI 3%–30%] vs. 15% [95% CI 4%–34%], LFS 64% [95% 
CI 40%–80%] vs. 80% [95% CI 55%–92%], OS 66% [95% 
CI 42%–82%] vs. 86% [95% CI 63%–95%]; all P  >  0.05). 
Likewise, patients with a C-KIT mutation at diagnosis 
(n  =  15) had 3-year CIR, LFS, and OS rates similar to 
patients without a C-KIT mutation at diagnosis (n = 30; 
CIR 14% [95% CI 2%–35%] vs. 14% [95% CI 5%–29%]; LFS 
79% [95% CI 49%–93%] vs. 69% [95% CI 48%–82%]; OS 
78% [95% CI 47%–92%] vs. 75% [95% CI 55%–87%]; all 
P > 0.05). Patients who had a positive MRD test (n = 19) 
had similar 3-year CIR, LFS, and OS rates as those who 
had a negative MRD test (n  =  26; CIR 11% [95% CI 
2%–28%] vs. 16% [95% CI 5%–33%]; LFS 68% [95% CI 
43%–84%] vs. 76% [95% CI 53%–88%]; OS 74% [95% CI 
48%–88%] vs. 79% [95% CI 57%–91%]; all P > 0.05).
Univariate and multivariate analyses in the combined 
population
WT1 transcript levels at diagnosis, C-KIT mutation state 
at diagnosis, MRD test results after the second cycle 
of consolidation chemotherapy, and subsequent ther-
apy received (chemotherapy only vs. allo-HSCT) were 
entered into multivariate analysis for CIR, LFS, and OS. 
All variables except C-KIT mutation state at diagno-
sis were independently associated with these outcomes 
(Table 3).
Comparison of outcomes between allo‑HSCT 
and chemotherapy within different risk groups
Of the 40 patients with low WT1 transcript levels at 
diagnosis, the 17 who received chemotherapy only had 
significantly lower LFS and OS rates than the 23 who 
received allo-HSCT (LFS: HR  =  6.70 [95% CI 2.63–
17.05], P  <  0.001; OS: HR  =  4.71 [95% CI 1.83–12.07], 
P  =  0.001). Of the 48 patients with high WT1 tran-
script levels at diagnosis, the 26 who received chemo-
therapy only had similar LFS and OS rates as the 22 
who received allo-HSCT (LFS: HR = 3.44 [95% CI 0.96–
12.41], P =  0.059; OS: HR =  2.66 [95% CI 0.63–11.16], 
P = 0.183).
Table 3 Multivariate analyses of  AML patients receiving 
chemotherapy only and allo-HSCT based on left-truncated 
Cox model
HR hazard ratio, CI confidence interval, WT1 Wilm tumor gene-1, MRD 
measureable residual disease, RUNX1-RUNX1T1 runt-related transcription factor 
1-RUNX1 translocation partner 1
a Patients with WT1 transcript levels ≤5.0% and >5.0% at diagnosis were 
characterized as having low and high WT1 transcript levels, respectively
b A less than and no less than 3-log reduction in RUNX1-RUNX1T1 transcript 
level compared to baseline (>0.4% and ≤0.4%) after the second cycle of 
consolidation chemotherapy were defined as positive and negative MRD test 
results, respectively
Variable No. of patients HR (95% CI) P value
Relapse
 Therapy
  Allo‑HSCT 45 1.00
  Chemotherapy only 43 11.49 (4.43–29.82) <0.001
 WT1 transcript levela
  High 48 1.00
  Low 40 3.53 (1.64–7.62) 0.001 
 MRD test resultb
  Negative 53 1.00
  Positive 35 2.30 (1.06–4.97) 0.034
Treatment failure
 Therapy
  Allo‑HSCT 45 1.00
  Chemotherapy only 43 5.85 (2.75–12.44) <0.001
 WT1 transcript level
  High 48 1.00
  Low 40 3.71 (1.82–7.56) <0.001
 MRD test result
  Negative 53 1.00
  Positive 35 2.33 (1.17–4.64) 0.016
Mortality
 Therapy
  Allo‑HSCT 45 1.00
  Chemotherapy only 43 4.34 (1.98–9.53) <0.001
 WT1 transcript level
  High 48 1.00
  Low 40 3.50 (1.56–7.82) 0.002
 MRD test result
  Negative 53 1.00
  Positive 35 2.32 (1.09–4.97) 0.030
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Discussion
Leukemia is one of the leading causes of cancer death 
[36]. AML is a type of heterogeneous leukemia. In the 
current study, we found that WT1 transcript level at diag-
nosis was significantly associated with CIR, LFS, and OS 
in patients with AML and t(8; 21) who achieved remission 
with conventional therapy. Although others have studied 
the prognostic effect of WT1 at diagnosis in patients with 
AML, the results are controversial; some studies reported 
that high WT1 transcript levels were associated with a 
good outcome [20–22], and others reported the contrary 
[23–26]. These studies included diverse populations and 
were not restricted to patients who achieved remission.
We also found an association between low WT1 tran-
script levels and C-KIT mutation at diagnosis. Others 
have reported similar results, but they examined fewer 
patients [37]. Martingale residual plot and ROC curve 
analyses indicated that a WT1 transcript level of  ≤5.0 
or >5.0% distinguished patients with different CIR, LFS, 
and OS probabilities.
Multivariate analyses showed that WT1 transcript lev-
els at diagnosis and results of MRD testing after the sec-
ond cycle of consolidation chemotherapy, but not C-KIT 
mutation at diagnosis, independently associated with CIR, 
LFS, and OS in patients who received chemotherapy only 
and in patients who received allo-HSCT. C-KIT mutation 
is a widely recognized adverse prognostic factor in AML 
patients with t(8; 21) [8, 10, 38–42]. Although WT1 lev-
els at diagnosis associated with C-KIT mutation, we also 
noted discordant results. We found that patients with 
either low WT1 transcript levels or a C-KIT mutation at 
diagnosis had poor prognosis despite achieving remission. 
However, WT1 levels at diagnosis were a better predictor 
of outcome than C-KIT mutation, and combining them 
enabled us to reclassify six patients as being at high-risk.
Our previous study suggested that allo-HSCT could 
improve the prognosis of high-risk patients with t(8;21) 
after 2–8 cycles of consolidation chemotherapy [13]. 
Multivariate analyses showed an independent association 
between therapy type and CIR, LFS, and OS.
Outcomes of patients with low WT1 transcript levels 
at diagnosis, whom we defined as high-risk, were better 
for those who received allo-HSCT than for those who 
received chemotherapy only. However, because patients 
with high WT1 transcript levels at diagnosis were not 
randomized to receive either allo-HSCT or chemother-
apy only, we cannot be certain that receiving allo-HSCT 
resulted in better outcomes.
Why low WT1 transcript levels at diagnosis are asso-
ciated with poor prognosis in patients with AML is 
unclear. WT1 functions are complex, including activa-
tion and repression of transcription and oncogenic and 
tumor-suppressor properties [43–46].
Our study has several important limitations. First, 
it was not randomized. Second, a substantial num-
ber of patients with a positive MRD test result declined 
their therapy assignment, including some patients who 
relapsed before allo-HSCT could be done. Third, MRD 
testing continued to be done at diverse time points fol-
lowing the analysis completed after the second consoli-
dation cycle. To interrogate associations of variables we 
analyzed with outcomes, we used the results of the test 
that was conducted after the second consolidation cycle 
in univariate and multivariate analyses; however, therapy 
recommendations were sometimes made based on test 
results from later time points. Fourth, the small sam-
ple size of subgroups resulted in relatively low statisti-
cal power. These considerations could have biased our 
results, and a randomized trial is warranted to test the 
validity of our conclusions.
Conclusions
Low WT1 transcript levels at diagnosis are associated 
with poor outcomes of AML patients with t(8;21) who 
achieve remission. Patients who received allo-HSCT 
instead of chemotherapy only had better outcomes. For 
patients with AML and t(8;21) with low WT1 transcript 
levels at diagnosis, a randomized trial of allo-HSCT 
versus chemotherapy only after consolidation chemo-
therapy is needed to determine if allo-HSCT improves 
outcomes.
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